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Avaliação da agregação plaquetária e dosagem do fibrinogênio em pacientes com doenças
cardiovasculares e sua correlação com o uso de aspirina e fatores de risco coronariano
Evaluation of platelet aggregation and level of
fibrinogen in patients with cardiovascular diseases
and the correlation of taking aspirin with coronary
risk factors
Abstract
Objective: To evaluate aspirin resistance in patients with
cardiovascular diseases and to compare the amount of serum
fibrinogen in patients taking aspirin with those who do not.
To correlate the platelet aggregation and serum fibrinogen
to cardiovascular risk parameters.
Method: Eighty-two patients were divided into two groups:
Group 1 - 41 patients who took 100mg aspirin daily and Group
2 - 41 patients who did not utilize platelet antiaggregates.
Epidemiological data were collected including age, gender
and information on smoking and alcohol intake and serum
fibrinogen and platelet aggregation were measured.
Results: In the groups analyzed, advanced age (p=0.011),
smoking (p=0.009) and alcoholism (p=0.007) were directly
associated to the serum fibrinogen level. There were no
correlations between smoking, alcoholism, serum fibrinogen
and platelet aggregation values (p>0.05). In Group 1, 29% of
the patients presented with aspirin resistance. Of these,
smokers (p=0.029) and alcoholics (p=0.033) had higher serum
fibrinogen levels.
Conclusion: Aspirin resistance was present in a high number
of patients. Moreover, advanced age, smoking and alcoholism
had a direct influence on the serum fibrinogen levels.
Descriptors: Fibrinogen. Platelet aggregation. Aspirin,
pharmacokinetics. Cardiovascular diseases.
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INTRODUCTION
Acetylsalicylic acid was commercially developed more
than 100 years ago in 1897 by Felix Hoffman and was
registered under the name aspirin [1]. The analgesic, anti-
inflammatory and antipyretic effects have been known for
centuries but only in 1971 did Sir John Vane describe the
platelet antiaggregant mechanism of aspirin which consists
of irreversible acetylation and inactivation of the
cyclooxygenase 1 enzyme [2].
Utilized in the primary and secondary prevention of
cardiovascular disease, aspirin reduces the prevalence of
myocardial infarction by 34%, strokes by 25%, pulmonary
thromboembolism by 67% and deep venous thrombosis by
23% [3]. The range of its protection is however limited with
its platelet antiaggregant effect not homogeneous for all
patients [4].
Recently some studies have warned about an inefficient
inhibition of platelet aggregation by aspirin [5-7]. This
phenomenon, denominated aspirin resistance, affects from
5% to 45% of patients with stable coronary artery disease,
suggesting that they will have fewer benefits in preventing
atherothrombotic events [7].
Many risk factors also affect the efficacy of aspirin
including advanced ages, smoking, alcohol consumption
and serum fibrinogen concentrations. Given the high
prevalence of cardiovascular diseases, the potential impact
of resistance to aspirin in the daily practice of physicians
and cardiovascular surgeons and the fact that risk factors
interfere in the efficacy of this medicine as a platelet
antiaggregant, we decided to design a study with the
following objectives: (1) to evaluate aspirin resistance in
cardiovascular disease patients, (2) to evaluate the level of
serum fibrinogen in patients taking aspirin compared to
others who do not take it and (3) to correlate platelet
aggregation and serum fibrinogen with parameters linked to
cardiovascular risk such as advanced age, smoking and
alcohol intake. We also highlight the role that this knowledge
may influence clinical and cardiovascular practices affecting
conduct and treatment of patients submitted to coronary
artery bypass grafting.
METHOD
Population
Eighty-two patients from the clinical wards of the Leonor
Mendes de Barros Hospital – Conjunction Hospital of
Sorocaba (CHS) participated in this study. Of these 82
patients, 41 took aspirin as their sole platelet antiaggregant
(Group 1) and 41 did not take any type of platelet
antiaggregant medication (Group 2 – control). Group 1
consisted of 15 women and 26 men all of whom suffered
from heart diseases diagnosed by electrocardiogram or
echocardiogram. The ages varied from 32 to 89 years old
with a mean age of 59.68 years. The Control Group was
formed of 29 female and 12 male patients without
cardiovascular diseases. The ages ranged from 30 to 75 years
old with a mean of 41.39 years.
Method
The clinical and demographical characteristics analyzed
included age, gender, smoking (packs per day), alcohol
Resumo
Objetivo: Avaliar a resistência à aspirina em pacientes
com doenças cardiovasculares. Avaliar a dosagem do
fibrinogênio sérico em pacientes usuários de aspirina,
comparando-a com os que não a utilizam. Correlacionar a
agregação plaquetária e o fibrinogênio sérico com parâmetros
ligados ao risco cardiovascular.
Método: Oitenta e dois pacientes divididos em dois grupos:
grupo 1 - 41 pacientes que utilizaram aspirina na dose de
100mg/dia e grupo 2 - 41 pacientes que não utilizaram
antiagregante plaquetário. Foram coletados dados
epidemiológicos quanto a idade, sexo, tabagismo, etilismo, e
foram realizadas dosagens de fibrinogênio sérico e agregação
plaquetária.
Resultados: Nos grupos analisados, a idade avançada
(p=0,011), o tabagismo (p=0,009) e o etilismo (p=0,007)
apresentaram associação direta com o fibrinogênio sérico.
Não houve correlação entre tabagismo, etilismo, fibrinogênio
sérico e os valores da agregação plaquetária (p>0,05). No grupo
1, 29% dos pacientes apresentaram resistência à aspirina.
Destes, os tabagistas (p=0,029) e os etilistas (p=0,033)
exibiram fibrinogênio sérico mais elevado.
Conclusão: A resistência à aspirina esteve presente em
número elevado de pacientes. Além disso, idade avançada,
tabagismo e etilismo influenciaram diretamente o
fibrinogênio sérico.
Descritores: Fibrinogênio. Agregação plaquetária.
Aspirina, farmacocinética. Doenças cardiovasculares.
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intake, serum fibrinogen concentration (mg/dL) and platelet
aggregation (%). Only patients taking 100 mg/day of aspirin
as a platelet antiaggregant for at least one week were included
in Group 1. Patients receiving doses higher or lower than
100 mg/day and patients taking other antithrombotic agents
with the aspirin were excluded from the study. All the patients
signed written consent forms and the research was approved
by the Local Ethics Committee (CCMB-PUC/SP).
Fibrinogen
Blood was drawn by venous puncture using disposable
Vacutainer-type equipment containing 2.7 mL 3.2% sodium
citrate as an anticoagulant. The STA Compact (Stago)
method was employed to measure the serum fibrinogen
concentration. Reference values are between 200 and 400
mg/dL. The laboratorial measurement of serum fibrinogen
concentrations was performed in the Regional Nucleus of
Hemotherapy of CHS.
Platelet aggregation
Blood was drawn by venous puncture using disposable
Vacutainer-type equipment containing 2.7 mL 3.2% sodium
citrate as an anticoagulant. The Born method was utilized to
measure platelet aggregation. This examination was performed
on the same day as blood collection. Reference values are
between 50% and 80%. The laboratorial measurement of
platelet aggregation was performed in the
SAE Laboratory. Patients with normal or
hyper aggregation in the platelet
aggregation examination although  they
were taking aspirin were considered
resistant to aspirin.
Statistical analysis
The SPSS (Statistical Package for
Social Sciences) version 13.0 computer
program was utilized to analyze the results.
Student t-test controlled by the Levene
test of variance equality was employed
with the aim of verifying differences
between the parametric variables; The
Mann-Whitney test was used to evaluate
possible differences in the distributions
of non-parametric variables and an
analysis using the Spearman correlation
to investigate possible associations
between the variables was made. A level
of significance of 5% (p-value < 0.05) was
adopted.
RESULTS
Of the 82 patients, 50% (41) took
aspirin at a dose on 100 mg/day (Group 1) for at least one
week whilst the other 50% (41) did not take this medication
(Group 2). The demographic and clinical characteristics
of both groups are described in Table 1. In this study, the
mean age of Group 1 was significantly higher than Group
2, revealing that older people take more aspirin. There are
more men among the patients who take aspirin confirming
that there is a greater incidence of cardiovascular events
among men whilst there are more women in the group
that does not take platelet antiaggregants. Moreover,
there are more smokers among the patients who require
the antiaggregants benefits of aspirin as the prevalence
of smokers is higher in Group 1. The majority of
individuals in both groups do not consume alcoholic
drinks and even so the greatest prevalence of consumers
was in Group 1. On average a higher serum fibrinogen
concentration was observed among the patients who took
aspirin. However there was no statistically significant
difference between the mean values of platelet
aggregation of the two groups.
The number of packs of cigarettes smoked per day was
evaluated and no significant difference was identified between
Groups 1 and 2 (p-value = 0.338). The mean number of packs of
cigarettes smoked in Group 1 was 1.32 with a standard deviation
of 0.54 while in Group 2, the individuals smoked 1.6 packs of
cigarettes with a standard deviation of 0.55.
Table 1. Demographic and clinical characteristics of patients
Age (years)
Gender
Smoker
Alcoholic
Fibrinogen*
Platelet aggregation **
Male
Female
yes
No
yes
No
Group 1
N=41
59.68 ± 16.55
63.4%
36.6%
34.1%
65.9%
22.0%
78.0%
357.71 ± 158.14
34.17% ± 30.77%
Data presented as mean ± standard deviation or percentage of patients * reference
value for serum fibrinogen concentration = 200 to 400mg/dL. ** reference value for
platelet aggregation = 50% to 80%. +Student t-test Student. § Mann-Whitney test.
Group 2 (control)
N=41
41.39 ± 17.19
29.3%
70.7%
12.2%
87.8%
4.9%
95.1%
277.90 ± 114.07
33.95% ± 23.83%
p-value
< 0.001+
0.002§
0.019§
0.024§
0.011+
0.971+
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Applying the Spearman coefficient, older patients (p-
value = 0.01), smokers (p-value = 0.009) and alcoholics (p-
value = 0.007) presented with higher serum fibrinogen
concentrations. Additionally, smokers (p-value = 0.001),
patients who consumed alcohol (p-value = 0.01) and patients
taking aspirin (p-value = 0.001) were older. The men were
older (p-value = 0.005), smoke more (p-value = 0.001), drink
more (p-value = 0.001) and take more aspirin (p-value = 0.002)
than women. The smokers drank more alcohol (p-value =
0.001) and took more aspirin (p-value = 0.018) compared to
those who do not smoke. The individuals who drank more
took more aspirin than those who did not drink (p-value =
0.023). No statistically significant differences were identified
between platelet aggregation levels and smoking,
consumption of alcohol and serum fibrinogen.
Twenty-nine percent (12) of the patients in Group 1
presented with normal or high levels of platelet aggregation
highlighting aspirin resistance in these patients. The
demographic and clinical data of patients from Group 1 (aspirin
resistant patients) are described in Table 2. In this study the
patients resistant to aspirin were younger, smoked more and
consumed more alcohol than patients not resistant to the
antiplatelet effects of aspirin. Patients resistant to aspirin were
predominantly male although there is a high percentage of
women who were also resistant to the beneficial effects of
aspirin. In respect to the serum fibrinogen, on average a higher
concentration was seen among the patients resistant to
aspirin. We also found statistical significance in the mean
values of platelet aggregation between the patients resistant
to aspirin and the group of patients not resistant to aspirin.
On evaluating the number of packs of cigarettes smoked
daily, there was no significant difference between the
resistant and non-resistant patients (p-value = 0.946). The
mean number of packs of cigarettes smoked by patients
resistant to aspirin was 1.33 with a standard deviation of
0.52, whilst for non-resistant patients the number was 1.31
with a standard deviation of 0.59.
Using the Spearman correlation, we observed that among
the patients resistant to aspirin, smokers (p-value = 0.029)
and patients who consumed alcohol (p-value = 0.033)
presented with higher levels of serum fibrinogen. Moreover,
smokers consumed more alcohol compared to those who
did not smoke (p-value = 0.01). Among patients not resistant
to aspirin, those who consumed alcohol presented with the
highest platelet aggregation levels (p-value = 0.006).
DISCUSSION
In this study, patients, who take aspirin as the sole platelet
antiaggregant, are a group of individuals that present per se
an increased cardiovascular risk as they are older, are
predominantly men, smoke more and have a higher
concentration of serum fibrinogen. The data here are
compatible to previously published reports as patients who
develop with coronary artery disease when young are
characterized by the presence of the aforementioned risk
factors amongst others including obesity, systemic arterial
hypertension, diabetes mellitus, unfavorable lipid profile,
high levels of apolipoprotein B and low levels of
apolipoprotein AI [8]. It is also important to stress that
currently the majority of patients submitted
to coronary artery bypass surgery are old,
male, smokers and in bad physical
conditions [9].
A significant association between age,
smoking, consumption of alcohol and
serum fibrinogen was observed in this
study, with older patients, smokers and
alcoholics presenting with high serum
fibrinogen concentrations. Our outcomes
agree with published results that serum
fibrinogen is an independent risk factor for
cardiovascular disease influenced by many
variables including age, smoking,
consumption of alcohol, infection,
hormone replacement therapy, body weight
and lipoprotein metabolism [10].
Serum fibrinogen concentrations
increase parallel to age which is the main
determinant [11,12]. Smoking on the other
hand, is the second most important factor
associated with fibrinogen [12,13], with
more marked alterations in women [13].
Table 2. Demographic and clinical characteristics of patients of Group 1
Age (years)
Gender
Smoker
Alcoholic
Fibrinogen*
Platelet aggregation **
Male
Female
yes
No
yes
No
Resistance to
Aspirin
N=12
55.33± 21.83
58.33%
41.67%
50%
50%
33.33%
66.67%
345.67± 167.22
76.92% ± 17.86%
Data presented as mean ± standard deviation or percentage of patients * reference
value for serum fibrinogen concentration = 200 to 400mg/dL. ** reference value for
platelet aggregation = 50% to 80%. +Student t-test Student. § Mann-Whitney test.
Not Resistant to
Aspirin
N=29
61.48 ± 13.88
65.52%
34.48%
27.59%
72.41%
17.24%
82.76%
362.69 ± 157.01
16.48% ± 10.96%
p-value
0.285+
0.724§
0.274§
0.436§
0.758+
< 0.001+
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Possible explanations for this are related to the inflammatory
reaction, endothelial injury, reduced fibrinolysis and platelet
activity induced by smoking [14].
The relationship between the consumption of alcoholic
drinks and the levels of serum fibrinogen however are still
controversial. In the study by Assanelli et al. [12], the
authors observed a direct association between the
consumption of alcohol and fibrinogen levels; whilst in
the study by Mukamal et al. [15] an inverse relationship
was observed. This divergence may be due to interference
of other factors on the levels of fibrinogen in the studied
group, suggesting the necessity of further studies to
elucidate possible interactions between the consumption
of alcohol and inflammatory markers, in particular serum
fibrinogen.
Serebruany et al. [16] affirm that moderate consumption
of alcohol (20 to 30 g/day) may reduce the risk of coronary
artery disease by at least 40%. This beneficial property of
alcohol is described for small to moderate quantities of
alcoholic drinks, as the ingestion of large quantities leads
to an increase in morbidity and mortality due to
cardiovascular diseases [17].
In respect to the efficacy of aspirin as a platelet
antiaggregant, the term aspirin resistance has received
special attention in current medical publications thanks to
its role in the day-to-day practice of clinicians and
cardiovascular surgeons. In our study, 29% of the patients
treated with 100mg/day aspirin alone demonstrated
resistance to the antiplatelet effects of aspirin. The data
obtained are less than the 60% reported by Mueller et al.
[18], utilizing the same dose of medication in patients
submitted to peripheral arterial angioplasty.
In our study, patients resistant to aspirin are younger,
smoke more, consume higher quantities of alcohol and have
lower serum fibrinogen concentrations than patients not
resistant to aspirin. These data suggest a possible influence
of the age, consumption of alcohol and serum fibrinogen on
the mechanisms responsible for aspirin resistance. In respect
to smoking our results do not agree with other publications
as smoking is a extrinsic factor in the loss of platelet
sensitivity to aspirin [5,6,19].
In this study no statistically significant correlation was
evidenced between platelet aggregation levels and smoking,
alcohol consumption and serum fibrinogen. Inoue et al. [20]
affirm however that platelet aggregation is potentially
accelerated in smokers. Miceli et al. [21] stress that, patients
who consume moderate quantities of alcohol, exhibit a
moderate but consistent inhibition of platelet aggregation.
Reininger et al. [22] considered a direct association between
the serum fibrinogen concentration and an increase in
platelet aggregation in patients with peripheral artery disease
after revascularization of the extremities.
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